Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
REGULATORY
COVID-19 Antibody Cocktail Given to 13,000 in Japan by August-End: MHLW
Chugai Pharmaceutical’s COVID-19 antibody cocktail Ronapreve (casirivimab + imdevimab) has been administered to an estimated 13,000 patients in Japan at roughly 1,700 facilities as of the end of August, the Japanese health ministry said on September 9. Ronapreve earned special…
To read the full story
Related Article
- Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
- Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
- Ronapreve Up for PAFSC Review for Preventive Use on Nov. 4
October 29, 2021
- Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
- Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
REGULATORY
- PMDA Announces Guidance on “Competing Products” in Regulatory Review
April 8, 2025
- MHLW Now Soliciting Bids for FY2025 Budget Projects to Fight Drug Lag/Loss
April 8, 2025
- Ishiba, Trump Agree to Appoint Ministers for Tariffs Talks
April 8, 2025
- Public-Private Council Will Meet This Summer: Japan PM
April 8, 2025
- Ishin Prods Govt to End Fee Incentives for Generic Use, Minister Says Topic Up for Chuikyo Discussions
April 7, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…